Histogen
Histogen Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing therapies using products derived from cells cultivated under simulated embryonic conditions. The company utilizes its innovative platform to produce human multipotent cell conditioned media and human extracellular matrix materials, which aim to replace and regenerate tissues in the body. Histogen's main focus is on stimulating patients' own stem cells through a complex of multipotent human proteins that promote stem cell growth and differentiation. Among its notable product candidates are HST-003 for joint cartilage repair and HST-004 for spinal disc repair. Additionally, Histogen is advancing a pipeline of small molecule inhibitors targeting infectious and inflammatory diseases, addressing significant gaps in therapeutic options within multi-billion dollar global markets.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.